サンプル依頼リスト カート
  • English
  • Korean
表紙：急性冠症候群の世界市場レポート 2024年
市場調査レポート
商品コード
1415732

急性冠症候群の世界市場レポート 2024年

Acute Coronary Syndrome Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
急性冠症候群の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

急性冠症候群市場規模は近年力強く成長しています。2023年の92億3,000万米ドルから2024年には98億6,000万米ドルへ、CAGR6.9％で成長します。実績期間の成長は、公衆衛生への取り組み、遠隔医療と遠隔モニタリングの採用、救急医療サービスの改善、患者教育の需要に起因しています。

急性冠症候群市場規模は、今後数年間で力強い成長が見込まれます。2028年の年間平均成長率（CAGR）は6.0%で124億4,000万米ドルに成長します。予測期間の成長は、個別化医療への需要、インターベンショナル心臓病学の増加、認知度の向上、世界の高齢化に起因しています。予測期間の主な動向には、診断ツールの進歩、医療情報技術の統合、迅速対応システム、技術の進歩などがあります。

急性冠症候群市場の成長は、冠動脈疾患、虚血性心疾患、血管疾患などの慢性疾患の有病率の増加によって促進されると予測されます。冠動脈の狭窄や閉塞を特徴とする虚血性心疾患は、そのような慢性疾患の一つです。急性冠症候群（ACS）の治療は、特に虚血性心疾患や血管性疾患などの患者に対して、症状を速やかに緩和し、心臓の損傷を最小限に抑え、さらなる合併症を予防することに重点を置いています。例えば、2022年8月にJournal of the American College of Cardiologyに発表された研究では、2025年から2060年にかけて、米国の一般人口の間で4つの心血管危険因子すべてが増加すると予測されていることが強調されました。脂質異常症は27.6％、高血圧は25.1％増加すると予測されました。また、心不全（33.4％）、虚血性心疾患（30.7％）、心筋梗塞（16.9％）、脳卒中（33.8％）も大幅に増加すると予測されました。このことは、冠動脈疾患、虚血性心疾患、血管疾患などの慢性疾患の蔓延が、急性冠症候群市場成長の原動力となっていることを裏付けています。

心臓疾患の発生率の増加は、急性冠症候群市場の成長を支える重要な原動力になると予想されます。心臓疾患には、冠動脈疾患、心不全、不整脈など、心臓や血管に影響を及ぼすさまざまな病状が含まれます。この心臓疾患の増加は、心筋への血流が減少または遮断される状態を伴うため、急性冠症候群（ACS）にとって極めて重要な役割を果たしています。このような症例の急増は、急性冠症候群治療に対する需要の増加につながっています。例えば、2022年3月に国家統計局が発表した報告書によると、2020年から2021年にかけて、心臓発作による死亡者数は19,440人から20,061人でした。さらに、2023年5月に疾病対策予防センターが発表したデータによると、米国では2021年、20歳以上の成人の20人に1人が心血管疾患に罹患していました。これは695,000人にのぼり、そのうちの375,476人が同年に心血管疾患で命を落としています。したがって、心臓疾患の罹患率の上昇は、急性冠症候群市場の成長を牽引する重要な力となっています。

北米は、2023年の急性冠症候群市場で最大の地域でした。急性冠症候群レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の急性冠症候群市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 非ST上昇型心筋梗塞
  • ST上昇型心筋梗塞
  • 不安定狭心症
  • 世界の急性冠症候群市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 薬剤
  • スタチン
  • ベータブロッカー
  • ACE阻害剤
  • 抗凝固剤
  • その他の治療
  • 世界の急性冠症候群市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ストレステスト
  • 血液検査
  • イメージング
  • その他の診断
  • 世界の急性冠症候群市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 非経口
  • 世界の急性冠症候群市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 専門クリニック
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の急性冠症候群市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の急性冠症候群市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 急性冠症候群市場の競合情勢
  • 急性冠症候群市場の企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson Limited
    • Siemens AG
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co. Inc.

第31章 その他の主要および革新的な企業

  • Bayer AG
  • Novartis AG
  • Sanofi-Aventis LLC.
  • Bristol-Myers Squibb Company
  • Thermo Fisher Scientific Inc.
  • AstraZeneca PLC
  • Abbott Laboratories
  • Medtronic Plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Co Ltd.
  • Stryker Corporation
  • GE Healthcare Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Regeneron Pharmaceuticals Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12331

“Acute Coronary Syndrome Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute coronary syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute coronary syndrome? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The acute coronary syndrome market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Non-St-Elevation Myocardial Infarction; St-Elevation Myocardial Infarction; Unstable Angina
  • 2) By Treatment: Medications; Statins; Beta blockers; ACE inhibitors; Anticoagulants; Other Treatment
  • 3) By Diagnosis: Stress Test; Blood Tests; Imaging; Other Diagnosis
  • 4) By Route Of Administration: Oral; Parenteral
  • 5) By End-User: Hospitals; Specialty clinics; Other End User
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; Siemens AG; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Acute coronary syndrome (ACS) encompasses a spectrum of clinical conditions resulting from a sudden reduction in blood flow to the heart. ACS is characterized by symptoms like chest pain or discomfort (angina), along with indicators of cardiac distress such as shortness of breath and dizziness. The primary objective in treating ACS is to swiftly alleviate symptoms, mitigate heart damage, and prevent potential complications.

There are three main types of acute coronary syndrome such as non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), and unstable angina. NSTEMI denotes a type of heart attack where one or more coronary arteries are partially or completely obstructed, leading to reduced blood supply to the heart muscle. Treatment modalities encompass medications like statins, beta-blockers, ACE inhibitors, anticoagulants, among others. Diagnostic procedures include stress tests, blood tests, various imaging techniques, and more. These treatments can be administered orally or through parenteral routes, and they are employed across a range of end-users including hospitals, specialty clinics, and others.

The acute coronary syndrome market research report is one of a series of new reports from The Business Research Company that provides acute coronary syndrome market statistics, including acute coronary syndrome industry global market size, regional shares, competitors with an acute coronary syndrome market share, detailed acute coronary syndrome market segments, market trends and opportunities and any further data you may need to thrive in the acute coronary syndrome industry. This acute coronary syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acute coronary syndrome market size has grown strongly in recent years. It will grow from $9.23 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to public health initiatives, adoption of telemedicine and remote monitoring, improved emergency medical services, demand for patient education.

The acute coronary syndrome market size is expected to see strong growth in the next few years. It will grow to $12.44 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to demand for personalized medicine, increase in interventional cardiology, increasing awareness, global aging population. Major trends in the forecast period include advancements in diagnostic tools, integration of health information technology, rapid response systems, technological advancements.

The growth of the acute coronary syndrome market is expected to be fueled by the increasing prevalence of chronic diseases like coronary artery disease, ischemic heart disease, and vascular diseases. Ischemic heart disease, characterized by the narrowing or obstruction of coronary arteries, is one such chronic condition. The treatment of acute coronary syndrome (ACS) focuses on promptly alleviating symptoms, minimizing heart damage, and preventing further complications, especially for patients dealing with conditions like ischemic heart disease and vascular diseases. For instance, in August 2022 a study published in the Journal of the American College of Cardiology highlighted an anticipated rise in all four cardiovascular risk factors among the general U.S. population from 2025 to 2060. Dyslipidemia was projected to increase by 27.6%, while hypertension by 25.1%. The study also noted significant anticipated increases in rates of heart failure (33.4%) and ischemic heart disease (30.7%), followed by heart attacks (16.9%) and strokes (33.8%). This underscores how the prevalence of chronic diseases, including coronary artery disease, ischemic heart disease, and vascular diseases, is a driving force behind the acute coronary syndrome market's growth.

The increasing incidence of cardiac disorders is expected to be a significant driver behind the growth of the acute coronary syndrome market. Cardiac disorders encompass a wide range of medical conditions affecting the heart or blood vessels, including coronary artery disease, heart failure, and arrhythmias. This rise in cardiac disorders plays a pivotal role in acute coronary syndrome (ACS) as it involves conditions where blood flow to the heart muscle is reduced or blocked. This surge in cases is leading to an increased demand for acute coronary syndrome treatments. For instance, in March 2022 a report published by the Office for National Statistics revealed that between 2020 and 2021, there were 19,440 to 20,061 reported deaths due to heart attacks. Furthermore, data from the Centers for Disease Control and Prevention in May 2023 indicated that in the US, 1 in 20 adults aged 20 and older were affected by cardiovascular diseases in 2021. This amounted to 695,000 individuals, with 375,476 of them succumbing to cardiovascular diseases that same year. Hence, the rising incidence of cardiac disorders is a significant force driving the growth of the acute coronary syndrome market.

The growth of the acute coronary syndrome market is expected to face hindrances due to the side effects associated with its treatment. Acute coronary syndrome typically requires a combination of drugs and procedures to restore blood flow and prevent further heart damage. While treatment for acute coronary syndrome is often beneficial, it is also associated with several adverse effects, including bleeding, low blood pressure, and allergic reactions. For instance, in September 2022, Merck & Co. Inc., a US-based pharmaceutical company, highlighted that aspirin, an antiplatelet drug used to reduce short- and long-term mortality risk in acute coronary syndrome patients, may lead to side effects such as gastrointestinal bleeding and ulcers. As a result, the presence of treatment-related side effects presents a challenge to the growth of the acute coronary syndrome market.

The key players in the acute coronary syndrome market are focusing on the development of groundbreaking drugs to advance the treatment of acute coronary syndrome and maintain their market standing. These innovations in drug development have the potential to enhance the effectiveness of ACS treatment, streamlining the process for each patient in terms of time and resources. For instance, in June 2023, AGEPHA Pharma USA LLC, a US-based pharmaceutical company, introduced Lodoco, the first anti-inflammatory atheroprotective cardiovascular treatment approved by the Food and Drug Administration (FDA). This medication is designed to reduce the risk of heart stroke, coronary revascularization, myocardial infarction (MI), and cardiovascular death in adult patients with cardiovascular diseases, including acute coronary syndrome.

In May 2023, Avertix Medical Inc., a US-based company specializing in the development of implantable patient alerting systems for acute coronary syndrome (ACS), entered a merger agreement with BIOS Acquisition Corporation for an approximate sum of $195 million. This strategic merger positions Avertix to enhance its commercial portfolio and further advance its innovative products, providing both patients and healthcare providers with state-of-the-art tools. BIOS Acquisition Corporation is a US-based incorporated blank check company.

Major players in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Terumo Corp., BioMerieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc .

North America was the largest region in the acute coronary syndrome market in 2023. The regions covered in acute coronary syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the acute coronary syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute coronary syndrome market consists of revenues earned by entities by providing various diagnoses through cardiac enzyme tests, blood tests and echocardiograms. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute coronary syndrome market also consists of sales of percutaneous coronary intervention (PCI) drugs and angiotensin-converting enzyme (ACE) inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Acute Coronary Syndrome Market Characteristics

3. Acute Coronary Syndrome Market Trends And Strategies

4. Acute Coronary Syndrome Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Acute Coronary Syndrome Market Size and Growth

  • 5.1. Global Acute Coronary Syndrome Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Acute Coronary Syndrome Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Acute Coronary Syndrome Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Acute Coronary Syndrome Market Segmentation

  • 6.1. Global Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Non-St-Elevation Myocardial Infarction
  • St-Elevation Myocardial Infarction
  • Unstable Angina
  • 6.2. Global Acute Coronary Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Medications
  • Statins
  • Beta blockers
  • ACE inhibitors
  • Anticoagulants
  • Other Treatment
  • 6.3. Global Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Stress Test
  • Blood Tests
  • Imaging
  • Other Diagnosis
  • 6.4. Global Acute Coronary Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Parenteral
  • 6.5. Global Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Specialty clinics
  • Other End User

7. Acute Coronary Syndrome Market Regional And Country Analysis

  • 7.1. Global Acute Coronary Syndrome Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Acute Coronary Syndrome Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Acute Coronary Syndrome Market

  • 8.1. Asia-Pacific Acute Coronary Syndrome Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Acute Coronary Syndrome Market

  • 9.1. China Acute Coronary Syndrome Market Overview
  • 9.2. China Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Acute Coronary Syndrome Market

  • 10.1. India Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Acute Coronary Syndrome Market

  • 11.1. Japan Acute Coronary Syndrome Market Overview
  • 11.2. Japan Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Acute Coronary Syndrome Market

  • 12.1. Australia Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Acute Coronary Syndrome Market

  • 13.1. Indonesia Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Acute Coronary Syndrome Market

  • 14.1. South Korea Acute Coronary Syndrome Market Overview
  • 14.2. South Korea Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Acute Coronary Syndrome Market

  • 15.1. Western Europe Acute Coronary Syndrome Market Overview
  • 15.2. Western Europe Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Acute Coronary Syndrome Market

  • 16.1. UK Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Acute Coronary Syndrome Market

  • 17.1. Germany Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Acute Coronary Syndrome Market

  • 18.1. France Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Acute Coronary Syndrome Market

  • 19.1. Italy Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Acute Coronary Syndrome Market

  • 20.1. Spain Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Acute Coronary Syndrome Market

  • 21.1. Eastern Europe Acute Coronary Syndrome Market Overview
  • 21.2. Eastern Europe Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Acute Coronary Syndrome Market

  • 22.1. Russia Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Acute Coronary Syndrome Market

  • 23.1. North America Acute Coronary Syndrome Market Overview
  • 23.2. North America Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Acute Coronary Syndrome Market

  • 24.1. USA Acute Coronary Syndrome Market Overview
  • 24.2. USA Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Acute Coronary Syndrome Market

  • 25.1. Canada Acute Coronary Syndrome Market Overview
  • 25.2. Canada Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Acute Coronary Syndrome Market

  • 26.1. South America Acute Coronary Syndrome Market Overview
  • 26.2. South America Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Acute Coronary Syndrome Market

  • 27.1. Brazil Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Acute Coronary Syndrome Market

  • 28.1. Middle East Acute Coronary Syndrome Market Overview
  • 28.2. Middle East Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Acute Coronary Syndrome Market

  • 29.1. Africa Acute Coronary Syndrome Market Overview
  • 29.2. Africa Acute Coronary Syndrome Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Acute Coronary Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Acute Coronary Syndrome Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Acute Coronary Syndrome Market Competitive Landscape And Company Profiles

  • 30.1. Acute Coronary Syndrome Market Competitive Landscape
  • 30.2. Acute Coronary Syndrome Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson Limited
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Siemens AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. F. Hoffmann-La Roche Ltd.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Merck & Co. Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Acute Coronary Syndrome Market Other Major And Innovative Companies

  • 31.1. Bayer AG
  • 31.2. Novartis AG
  • 31.3. Sanofi-Aventis LLC.
  • 31.4. Bristol-Myers Squibb Company
  • 31.5. Thermo Fisher Scientific Inc.
  • 31.6. AstraZeneca PLC
  • 31.7. Abbott Laboratories
  • 31.8. Medtronic Plc
  • 31.9. Takeda Pharmaceutical Company Limited
  • 31.10. Eli Lilly and Co Ltd.
  • 31.11. Stryker Corporation
  • 31.12. GE Healthcare Inc.
  • 31.13. Boehringer Ingelheim International GmbH
  • 31.14. Boston Scientific Corporation
  • 31.15. Regeneron Pharmaceuticals Inc.

32. Global Acute Coronary Syndrome Market Competitive Benchmarking

33. Global Acute Coronary Syndrome Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Acute Coronary Syndrome Market

35. Acute Coronary Syndrome Market Future Outlook and Potential Analysis

  • 35.1 Acute Coronary Syndrome Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Acute Coronary Syndrome Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Acute Coronary Syndrome Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer